Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants
Saved in:
| Published in: | PLOS Neglected Tropical Diseases Atom |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants
- Mapping the last mile: Micro-stratification for sustained visceral leishmaniasis elimination in Bangladesh
- Hiding in plain sight: A call to prevent cutaneous leishmaniasis transmission in the United States
- Seroprevalence of canine leishmaniasis in Kwara, Oyo and Ogun states of Nigeria
- Assessment of the implementation of action plan against cutaneous leishmaniasis in Morocco: case of Essaouira focus
- Revisiting the largest human leishmaniasis outbreak in Western Europe (Madrid, Spain): a follow-up entomological study in 2023 and 2024
- Biodistribution, radiodosimetry and pharmacokinetics of [F]GSK1482160 for cerebral P2X7 receptor in living subjects